0000818479-26-000147
SEC filingDENTSPLY SIRONA reported Q1 2026 GAAP net sales of $880 million (+0.1% YoY), GAAP net loss of $10 million, and adjusted EPS of $0.27, reaffirming its full-year 2026 outlook of $3.5–$3.6 billion in net sales and $1.40–$1.50 in adjusted EPS.
DENTSPLY SIRONA’s Q1 2026 results reflect continued execution of its Return-to-Growth Action Plan amid external pressures and investment timing, as stated by CEO Dan Scavilla. Net sales grew nominally (+0.1% YoY to $880M) but declined (6.7)% on a constant-currency basis, underscoring meaningful foreign exchange drag. Gross margin compression—down 450 bps to 48.5%—was driven by lower gross profit ($427M vs. $466M YoY), likely tied to product mix shifts, inflationary input costs, or commercial restructuring impacts. The GAAP net loss of $10M contrasts sharply with $20M net income in Q1 2025, largely due to elevated restructuring and other costs ($67M vs. $9M), higher R&D spend ($44M vs. $36M), and a $32M tax benefit that partially offset the pre-tax loss. Adjusted metrics show underlying operational strain: adjusted EBITDA fell 22.8% YoY to $129M, and adjusted EPS dropped 39.0% to $0.27—both materially below analyst consensus of $0.28 for the quarter. Despite this, management reiterated full-year guidance, citing early traction in distributor partnerships (e.g., Atlanta Dental Supply, Benco Dental), innovation milestones (Smart View-Detect launch), and progress on working capital and liquidity management. Operating cash flow more than quintupled to $40M, reflecting improved collections, though free cash flow remained negative at ($12M), consistent with prior year. The balance sheet remains stable, with $190M in cash as of March 31, 2026, supporting ongoing transformation investments without immediate liquidity risk. Investors should monitor sequential margin recovery, distributor adoption velocity, and whether second-half execution delivers the anticipated momentum referenced in management commentary.